ReviewMetabolic brain disease2013
Role of diabetes mellitus on hepatic encephalopathy.
Review in Metabolic brain disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt.Alimentary pharmacology & therapeutics · 2026Article
- Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure.Hepatology international · 2026Observational
- Associations of metabolic syndrome with minimal hepatic encephalopathy in patients with cirrhosis and portal hypertension: a retrospective cohort study.Frontiers in behavioral neuroscience · 2026Article
- β-Glucan Alone or Combined with Lactobacillus acidophilus Positively Influences the Bacterial Diversity and Metabolites in the Colonic Microbiota of Type II Diabetic Patients.Probiotics and antimicrobial proteins · 2025Article
- Risk factors for hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A comprehensive minireview.World journal of hepatology · 2025Review
- The crucial role of risk factors when dealing with hepatic Encephalopathy.Metabolic brain disease · 2024Review
- Thyroid Hormone Neuroprotection Against Perfluorooctane Sulfonic Acid Cholinergic and Glutamatergic Disruption and Neurodegeneration Induction.Biomedicines · 2024Article
- Hepatic encephalopathy.Nature reviews. Disease primers · 2022Review
- Hepatic Encephalopathy and Melatonin.Antioxidants (Basel, Switzerland) · 2022Review
- Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy.Scientific reports · 2022Article
- Impact ofJournal of neurogastroenterology and motility · 2021Article
- Association of Type 2 Diabetes and Hepatic Encephalopathy in Chronic Liver Disease Patients.Cureus · 2021Article
- Effect of type 2 diabetic mellitus in the prognosis of acute-on-chronic liver failure patients in China.World journal of gastroenterology · 2021Article
- Graph Embedding Based Novel Gene Discovery Associated With Diabetes Mellitus.Frontiers in genetics · 2021Article
- Minimal/Covert Hepatic Encephalopathy - Impact of Comorbid Conditions.Journal of clinical and experimental hepatologyReview
- Special Section: Update in Hepatic Encephalopathy- Part III.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy is the main cognitive dysfunction in cirrhotic patients associated with impaired prognosis. Hyperammonemia plus inflammatory response do play a crucial role on hepatic encephalopathy. However, in some patients HE appeared without hyperammonemia and patients with increased levels of ammonia could not show cognitive dysfunction. This has led to investigate other factors that could act in a synergistic way. Diabetes mellitus and insulin resistance are characterized by releasing and enhancing these pro-inflammatory cytokines and, additionally, has been related to hepatic encephalopathy. Indeed, patients with diabetes showed raised risk of over hepatic encephalopathy in comparison with non-cirrhotics. Type 2 diabetes mellitus could impair hepatic encephalopathy by different mechanisms that include: a) increasing glutaminase activity; b) impairing gut motility and promoting constipation, intestinal bacterial overgrowth and bacterial translocation. Despite of insufficient clarity about the practicability of anti-diabetic therapy and the most efficacious therapy, we would have to pay a special attention to the management of type 2 diabetes mellitus and insulin resistance in cirrhotic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.